Sage Therapeutics, Inc. stock price

Sage Therapeutics, Inc. latest news:


  • 09/15/2017 15:10:21

    Neos Therapeutics shares fall after FDA approves new formulation of ADHD drug

    Shares of Neos Therapeutics Inc. fell more than 5% late Friday after the pharmaceutical company said the U.S. Food and Drug Administration has approved one of its extended-release drugs for Attention Deficit Hyperactive Disorder in an oral-suspension form. "This FDA approval unlocks yet another treatment option for ADHD patients and their caregivers who are seeking a liquid extended-release amphetamine product and provides a different dosage form of our already-approved Adzenys XR-ODT," Neos Therapeutics Chief Vipin K. Garg said in a statement. The FDA has aproved three ADHD drugs by Neos in two years, which "speaks to the strength of our technology platform," he said. The new formulation is expected to be commercially launched in early 2018, the company said. The shares ended the regular trading day up 2.2%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/12/2017 14:31:16

    DowDuPont and US Bancorp climb while Cooper Cos. slides

    DowDuPont and US Bancorp advance while Cooper Cos. and Sage Therapeutics falls

  • More trends:

    Sagent Pharmaceuticals, Inc.SGNT | Saia, Inc.SAIA | Sajan, Inc.SAJA | Salem Media Group, Inc.SALM | Salisbury Bancorp, Inc.SAL | Sanderson Farms, Inc.SAFM | SanDisk CorporationSNDK | Sandy Spring Bancorp, Inc.SASR | Sangamo BioSciences, Inc.SGMO | Sanmina CorporationSANM |